Historical Valuation
Citius Pharmaceuticals Inc (CTXR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.28 is considered Undervalued compared with the five-year average of -5.03. The fair price of Citius Pharmaceuticals Inc (CTXR) is between 14.00 to 15.27 according to relative valuation methord. Compared to the current price of 0.90 USD , Citius Pharmaceuticals Inc is Undervalued By 93.57%.
Relative Value
Fair Zone
14.00-15.27
Current Price：0.90
93.57%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Citius Pharmaceuticals Inc (CTXR) has a current Price-to-Book (P/B) ratio of 0.23. Compared to its 3-year average P/B ratio of 1.04 , the current P/B ratio is approximately -78.25% higher. Relative to its 5-year average P/B ratio of 1.45, the current P/B ratio is about -84.32% higher. Citius Pharmaceuticals Inc (CTXR) has a Forward Free Cash Flow (FCF) yield of approximately -150.81%. Compared to its 3-year average FCF yield of -71.42%, the current FCF yield is approximately 111.15% lower. Relative to its 5-year average FCF yield of -47.66% , the current FCF yield is about 216.41% lower.
P/B
Median3y
1.04
Median5y
1.45
FCF Yield
Median3y
-71.42
Median5y
-47.66
Competitors Valuation Multiple
AI Analysis for CTXR
The average P/S ratio for CTXR competitors is 17.83, providing a benchmark for relative valuation. Citius Pharmaceuticals Inc Corp (CTXR.O) exhibits a P/S ratio of 0.28, which is -98.45% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CTXR
1Y
3Y
5Y
Market capitalization of CTXR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CTXR in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CTXR currently overvalued or undervalued?
Citius Pharmaceuticals Inc (CTXR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.28 is considered Undervalued compared with the five-year average of -5.03. The fair price of Citius Pharmaceuticals Inc (CTXR) is between 14.00 to 15.27 according to relative valuation methord. Compared to the current price of 0.90 USD , Citius Pharmaceuticals Inc is Undervalued By 93.57% .
What is Citius Pharmaceuticals Inc (CTXR) fair value?
CTXR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Citius Pharmaceuticals Inc (CTXR) is between 14.00 to 15.27 according to relative valuation methord.
How does CTXR's valuation metrics compare to the industry average?
The average P/S ratio for CTXR's competitors is 17.83, providing a benchmark for relative valuation. Citius Pharmaceuticals Inc Corp (CTXR) exhibits a P/S ratio of 0.28, which is -98.45% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Citius Pharmaceuticals Inc (CTXR) as of Jan 10 2026?
As of Jan 10 2026, Citius Pharmaceuticals Inc (CTXR) has a P/B ratio of 0.23. This indicates that the market values CTXR at 0.23 times its book value.
What is the current FCF Yield for Citius Pharmaceuticals Inc (CTXR) as of Jan 10 2026?
As of Jan 10 2026, Citius Pharmaceuticals Inc (CTXR) has a FCF Yield of -150.81%. This means that for every dollar of Citius Pharmaceuticals Inc’s market capitalization, the company generates -150.81 cents in free cash flow.
What is the current Forward P/E ratio for Citius Pharmaceuticals Inc (CTXR) as of Jan 10 2026?
As of Jan 10 2026, Citius Pharmaceuticals Inc (CTXR) has a Forward P/E ratio of 0.45. This means the market is willing to pay $0.45 for every dollar of Citius Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Citius Pharmaceuticals Inc (CTXR) as of Jan 10 2026?
As of Jan 10 2026, Citius Pharmaceuticals Inc (CTXR) has a Forward P/S ratio of 0.28. This means the market is valuing CTXR at $0.28 for every dollar of expected revenue over the next 12 months.